RegeneRx Biopharmaceuticals Total Current Liabilities

RegeneRx Biopharmaceuticals (RGRX) currently reports a total current liabilities of $0 as of September 2023. That compares with $480K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore RegeneRx Biopharmaceuticals's total current liabilities history and peer comparisons.

RegeneRx Biopharmaceuticals's total current liabilities decreased from $480K to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RegeneRx Biopharmaceuticals reported $0 in total current liabilities as of September 2023. That compares with $480K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for RegeneRx Biopharmaceuticals, and consider following RGRX for alerts when major investors trade the stock.

RegeneRx Biopharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGRX with unrelated industries.